7 completed, 1 recruiting, 1 unknown. 3 Phase 1, 3 Phase 3, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow Chugai Pharma USA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment Codrituzumab - Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3) | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2021-06-09 | 2026-10-26 |
| RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer RO5126766 - Advanced Non-small Cell Lung Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 15 | 2018-10-31 | 2024-07-10 |
| Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia® Spectra Optia® IDL-Set, Spectra Optia® Collection Set - Healthy Allogeneic Donors, Granulocyte Colony-stimulating Factor (G-CSF) Mobilized | Not applicable | Completed | Heinrich-Heine University, Duesseldorf | 50 | 2014-03-01 | 2015-03-19 |
| A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment Ofatumumab, Chlorambucil, Bendamustine - Chronic Lymphocytic Leukaemia | Phase 3 | Unknown | University of Liverpool | 670 | 2011-12-01 | 2012-10-15 |
| Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC) Erlotinib, taxotere - Non Small Cell Lung Cancer | Completed | Groupe Francais De Pneumo-Cancerologie | 100 | 2006-05-01 | 2013-10-01 | |
| Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial FEC-DocGemzar adjuvant chemotherapy, FEC-Doc adjuvant chemotherapy, Zoledronic acid i.v. 2 years - Breast Neoplasms | Phase 3 | Completed | Ludwig-Maximilians - University of Munich | 3754 | 2005-09-01 | 2014-07-03 |
| Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis GM-611 - Gastroparesis | Phase 2 | Completed | Chugai Pharma USA | 2005-06-24 | ||
| An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer CAL - Breast Neoplasms, Breast Cancer | Phase 1 | Completed | Chugai Pharma USA | 2005-06-24 | ||
| A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels. BO-653 - Graft Occlusion, Vascular, Coronary Restenosis | Phase 2 / Phase 3 | Completed | Chugai Pharma USA | 2005-06-24 |
Breast Neoplasms (2) · Atherosclerosis (1) · Carcinoma, Non-Small-Cell Lung (1) · Coronary Restenosis (1) · Gastroparesis (1) · Graft Occlusion, Vascular (1) · Hepatoblastoma (1) · Hypercalcemia (1) · Leukemia, B-Cell (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Recurrence (1) · Simpson-Golabi-Behmel syndrome (1)
2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran (1) · Bendamustine Hydrochloride (1) · Chlorambucil (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · RO5126766 (1) · codrituzumab (1) · mitemcinal (1) · ofatumumab (1)
United States (5) · Germany (2) · France (1) · United Kingdom (1)
Gregory Riely, MD, PhD (1) · Harald L Sommer, Prof. Dr. med. (1) · Johannes C Fischer, MD (1) · Michael Ortiz, MD (1)
PMID 26385214, PMID 27387743, PMID 27464822, PMID 30690254, PMID 33097092, PMID 34165508, PMID 40313965, PMID 42696691
2005 (1)